Finance

With $106M series C, Tenaya will bring AAV manufacturing in-house

The company will also advance three heart disease platforms in parallel

With $106 million in new series C funding, Tenaya will internalize its AAV manufacturing capabilities and continue to advance its suite of gene therapy, cellular regeneration and precision medicine